Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 19/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 15/20 | 0.69 |
| ▸ | SIRT3 | Q9NTG7 | 12/20 | 0.69 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | CTSS | P25774 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20542972 | 1.00 | SIRT2 (0.69) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL20542671 | 1.00 | SIRT2 (0.69) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL20542673 | 1.00 | SIRT2 (0.69) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL11737428 | 0.92 | CTSL (0.76) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL16782306 | 0.90 | SIRT2 (0.66) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20542967 | 0.90 | SIRT2 (0.66) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20542970 | 0.90 | SIRT2 (0.66) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20542985 | 0.90 | SIRT2 (0.66) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20542983 | 0.90 | SIRT2 (0.66) | SIRT2SIRT1SIRT3 | |
| SCHEMBL8766104 | 0.89 | CTSL (0.76) | SIRT2SIRT1SIRT3CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | AJINOMOTO CO., INC. (JP) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180311342-A1 | IMMUNOSTIMULATING AGENT | MYD88, TLR9, IL2 | SIRT2 990/4885SIRT1 1226/4885SIRT3 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.